INTERNATIONAL BIOTECHNOLOGY TRUST PLC

1. INTERNATIONAL BIOTECHNOLOGY TRUST PLC 1994-02-23 → present
2. HACKPLIMCO (NO. FOURTEEN) PUBLIC LIMITED COMPANY 1994-01-31 → 1994-02-23

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

IFRS

Reporting scope

Standalone (parent only)

Auditor

PricewaterhouseCoopers LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The Directors assessed the viability of the Company over a five year period, having regard to the Company's financial position at 31 August 2025, and the principal risks. The Directors have concluded that the Company will be able to continue in operational existence and to meet all its liabilities as they fall due over the five year period of their assessment.”

Group structure

1. INTERNATIONAL BIOTECHNOLOGY TRUST PLC · parent
   1. Top/Vert 12.01% · UK
   2. Top/Vert 19.65% · UK
   3. SV BCOF 11.2% · Venture fund
   4. SV Fund VI 7.7% · Venture fund

Significant events

• “The Board approved the payment of a final dividend of 16.17p per share for the year ended 31 August 2025.”
• “The first interim dividend of 16.17p was paid.”
• “At 31 August 2025, 41,383,817 ordinary shares were in issue.”
• “After the year end and up to 4 November 2025, 1,351,308 ordinary shares were bought back to be held in treasury.”
• “On 4 November 2025, the Company signed a deed of amendment and restatement of an amended and restated AIFM agreement to amend the basis under which a quoted performance fee is payable.”
• “On 11 October 2024, the Company announced the establishment of a new limited partnership ('the Partnership') through which the Company intends over time to invest in further unquoted biotechnology opportunities.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

20

last 12 months

Capital events

12

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  —

  Not reported

• Cash

  +43.6%

  £10,433,000 → £14,980,000

• Net assets

  -11.6%

  £282,265,000 → £249,409,000

• Employees

  —

  Not reported

• Profit before tax

  -109.5%

  £42,372,000 → -£4,031,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers